* Says meets second-year milestones
* Platform allows large-scale production of DNA vaccines
June 18 (Reuters) - Vical Inc (VICL.O) said it is taking the development of its DNA vaccine manufacturing process into the third year, under a $6 million grant from the National Institutes of Health, after meeting its second-year milestones.
The RapidResponse system significantly reduces the time required to develop, manufacture and deploy vaccines against emerging diseases during the early stages of an infectious outbreak, the company said in a statement.
Vical said the system is ideally suited against diseases like H1N1 or H5N1 pandemic influenza or severe acute respiratory syndrome (SARS).
For the alerts, please double-click [ID:nWNAB0913] (Reporting by Shailesh Kuber in Bangalore; Editing by Deepak Kannan)